Company: TAK
Filing Date: 2025-06-06
Form Type: 6-K
Source: 0001395064-25-000076
Chunk: 1

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-06
Form: 6-K
Chunk 1
---
 Takeda,
in Response to Institutional Shareholder Services Inc.’s Voting Recommendations
Ahead of the 149</div>

#### th

#### Annual General Meeting of Shareholders
Dear Takeda Shareholder,

On behalf of Takeda’s Board of Directors, I would like to express our firm objection again this year to Institutional Shareholder Services Inc. (ISS)’s recommendations that Takeda shareholders vote against the re-election of Christophe Weber to the Board (Proposal 2.1) and against the approval of bonuses for internal directors (Proposal 3) at the 149 th Annual General Meeting of Shareholders.

We request that shareholders, when making their voting decisions, consider holistically Mr. Weber’s strategic vision and execution to position Takeda for long-term growth and maximize value for Takeda’s shareholders.

Under Mr. Weber’s leadership, Takeda has transformed into a truly global, values-based, innovation-driven biopharmaceutical company. As the result of his strategic initiatives, the company now has one of the most competitive late-stage pipelines in the industry, and the commercial scale and capabilities to successfully launch these innovative medicines worldwide. 2025 will be a pivotal year for Takeda, with Phase 3 data readouts expected for three high-potential pipeline assets, rusfertide, oveporexton, and zasocitinib, all of which have the potential to deliver significant value to patients and to shareholders.

The company is also well positioned today to be resilient within the ever-evolving geopolitical landscape, with a robust global supply chain, balanced geographical footprint, and responsible approach to intellectual property and tax strategies.

As part of the transformation, the company has taken strategic initiatives which have impacted reported financial metrics such as Return on Equity (ROE) - for example, purchase price accounting expenses related to strategic M&A. When making their voting decisions, we request that shareholders assess Mr. Weber’s leadership based on a comprehensive consideration of his achievement in transforming the Company to be truly competitive within the rapidly evolving global pharmaceutical market, and not just focus on reported profit metrics over a limited time period.

The Board also believes that it is critical to retain and motivate Takeda senior management by compensating them in a manner that is competitive within the global pharmaceutical market.

The level and mix of compensation for Takeda’s Internal Directors are reviewed and established each year by the Compensation Committee, comprised of four independent External Directors, in consultation with an independent compensation consultant. The Committee benchmarks against comparable executives